David Einhorn Still Thinks His Green Mountain Short Can ‘Pan Out’

Hedge fund manager David Einhorn was on Bloomberg TV earlier today, and he was talking about everything from the U.S. economy to some of his most widely covered positions. As the news site pointed out, Einhorn called a U.S. default “unimaginable,” adding that the situation is “embarrassing.” Greenlight Capital’s founder also shared his thoughts on his Green Mountain Coffee Roasters (NASDAQ:GMCR) short as well as the moderately sized long position he holds in Vodafone (NASDAQ:VOD).

GREENLIGHT CAPITAL David Einhorn

Barron’s was listening in to the entire conversation, and it noted that Einhorn still thinks Green Mountain can “pan out” on the short side even though it has had a great 2013. According to the Focus on Funds blog, here were his thoughts on GMCR:

The competition is increasing, their market share in their stores is declining. I think they’re going to miss on the earnings side some time in the next year. And I think people are going to wake up at some point and say these earnings are not what they appear to be.

So that’s a bit surprising, we’ve got to admit, and Einhorn’s thoughts on Vodafone were a bit more on script. He said that Vodafone deserved an “A+” for its recent decision to sell its 49% joint venture stake in Verizon Wireless to Verizon (NYSE:VZ).

Does that mean Green Mountain’s three straight earnings beats get an “F” for destroying his short thesis this year?

Disclosure: none

Recommended Reading:

David Einhorn’s Top Stocks Dominate the Market Even Though Greenlight Capital Doesn’t

Apple Versus Microsoft: What Do Hedge Funds Think?

Carl Icahn’s Best Pick Isn’t Apple; These Stocks Are

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!